Commentary

Video

Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer

Author(s):

Christian Marth, MD, PhD

Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Related Content
Neoadjuvant Dostarlimab in dMMR Solid Tumors | Image credit: © Thipphaphone – stock.adobe.com
April 29th 2025

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Pembrolizumab/Concurrent Chemoradiation in High-Risk, Locally Advanced Cervical Cancer
April 14th 2025

Pembrolizumab Plus Concurrent Chemoradiation Represents New SOC for High-Risk, Locally Advanced Cervical Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Bevacizumab biosimilar Jobevne | Image Credit: © Man888 – stock.adobe.com
April 10th 2025

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

Cadonilimab/Lenvatinib in Endometrial Cancer | Image Credit: © LASZLO - stock.adobe.com
April 8th 2025

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer